OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy

Stock Information for OncoSec Medical Incorporated

Loading

Please wait while we load your information from QuoteMedia.